|
Asian Journal of Andrology (2012) 14, 393-399; doi:10.1038/aja.2011.145; published online 16 April 2012
ETS rearrangements in prostate cancer
Mark A Rubin
Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY 10065, USA
Correspondence: Dr MA Rubin, (rubinma@med.cornell.edu)
Received 15 December 2011; Revised 13 January 2012; Accepted 20 January 2012
Advance online publication 16 April 2012.
| Abstract |
Prostate cancer is a clinically and molecularly heterogeneous disease. Understanding the biologic underpinning of prostate cancer is necessary to best determine how biology is associated with the risk of disease progression and how this understanding might provide insight into the development of novel therapeutic approaches. The focus of this review is on the recently identified common ETS and non-ETS gene rearrangements in prostate cancer. Although multiple molecular alterations have been detected in prostate cancer, a basic understanding of gene fusion prostate cancer should help explain the clinical and biologic diversity, providing a rationale for a molecular subclassification of the disease.
Keywords: ETS; gene fusion; next generation sequencing; prostate cancer; TMPRSS2:ERG; translocation |
|
